Free Trial
NASDAQ:CYCC

Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis

Cyclacel Pharmaceuticals logo
$7.99 -0.01 (-0.13%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$8.03 +0.04 (+0.50%)
As of 08/22/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC)

Key Stats

Today's Range
$7.79
$8.16
50-Day Range
$0.23
$17.15
52-Week Range
$3.08
$597.60
Volume
42,660 shs
Average Volume
248,458 shs
Market Capitalization
$17.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Cyclacel Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
10th Percentile Overall Score

CYCC MarketRank™: 

Cyclacel Pharmaceuticals scored higher than 10% of companies evaluated by MarketBeat, and ranked 897th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cyclacel Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cyclacel Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cyclacel Pharmaceuticals has a P/B Ratio of 4.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Cyclacel Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    6.39% of the float of Cyclacel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclacel Pharmaceuticals has recently decreased by 17.95%, indicating that investor sentiment is improving significantly.
  • Percentage of Shares Shorted

    6.39% of the float of Cyclacel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclacel Pharmaceuticals has recently decreased by 17.95%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Cyclacel Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for CYCC on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cyclacel Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,430.00 in company stock.

  • Percentage Held by Insiders

    51.20% of the stock of Cyclacel Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions.

  • Read more about Cyclacel Pharmaceuticals' insider trading history.
Receive CYCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CYCC Stock News Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
See More Headlines

CYCC Stock Analysis - Frequently Asked Questions

Cyclacel Pharmaceuticals' stock was trading at $90.24 at the start of the year. Since then, CYCC stock has decreased by 91.1% and is now trading at $7.99.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) issued its quarterly earnings results on Wednesday, August, 13th. The biotechnology company reported ($0.98) earnings per share for the quarter, beating analysts' consensus estimates of ($72.00) by $71.02.

Cyclacel Pharmaceuticals shares reverse split on the morning of Monday, July 7th 2025.The 1-15 reverse split was announced on Wednesday, July 2nd 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclacel Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/13/2025
Today
8/24/2025
Next Earnings (Estimated)
11/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CYCC
CIK
1130166
Employees
14
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($839.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.21 million
Net Margins
N/A
Pretax Margin
-54,220.00%
Return on Equity
-723.64%
Return on Assets
-145.51%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.77
Quick Ratio
5.60

Sales & Book Value

Annual Sales
$10 thousand
Price / Sales
1,788.96
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.62 per share
Price / Book
4.93

Miscellaneous

Outstanding Shares
2,239,000
Free Float
1,093,000
Market Cap
$17.89 million
Optionable
Optionable
Beta
0.08

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:CYCC) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners